Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/161735
Registo completo
Campo DCValorIdioma
dc.creatorChitas, R-
dc.creatorNunes, C-
dc.creatorReis, S-
dc.creatorParreira, P-
dc.creatorMartins, MCL-
dc.date.accessioned2024-10-04T16:56:26Z-
dc.date.available2024-10-04T16:56:26Z-
dc.date.issued2022-
dc.identifier.issn1999-4923-
dc.identifier.urihttps://hdl.handle.net/10216/161735-
dc.description.abstractThe major risk factor associated with the development of gastric cancer is chronic infection with Helicobacter pylori. The available treatments, based on a cocktail of antibiotics, fail in up to 40% of patients and disrupt their gut microbiota. The potential of blank nanostructured lipid carriers (NLC) for H. pylori eradication was previously demonstrated by us. However, the effect of NLC charge, size and protein corona on H. pylori-specific bactericidal activity herein studied was unknown at that time. All developed NLC formulations proved bactericidal against H. pylori. Although cationic NLC had 10-fold higher bactericidal activity than anionic NLC, they lacked specificity, since Lactobacillus acidophilus was also affected. Anionic NLC achieved complete clearance in both H. pylori morphologies (rod- and coccoid-shape) by inducing alterations in bacteria membranes and the cytoplasm, as visualized by transmission electron microscopy (TEM). The presence of an NLC protein corona, composed of 93% albumin, was confirmed by mass spectrometry. This protein corona delayed the bactericidal activity of anionic NLC against H. pylori and hindered NLC activity against Escherichia coli. Overall, these results sustain the use of NLC as a promising antibiotic-free strategy targeting H. pylori.pt_PT
dc.description.sponsorshipThis work was financed by the FCT-Fundação para a Ciência e a Tecnologia through projects POCI-01-0145-FEDER-007274, PyloriBinders-Helicobacter pylori specific biomaterials for antibiotic-free treatment/diagnostic of gastric infection, UIB/50006/2020 (LAQV-REQUIMTE). Rute Chitas (SFRH/BD/151081/2021), Paula Parreira (CEECIND/01210/2018) and Maria Cristina L. Martins (LA/P/0070/2020) also thank FCT for funding. Maria Cristina L. Martins also acknowledges the MOBILIsE Project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 951723.pt_PT
dc.language.isoengpt_PT
dc.publisherMDPIpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/OE/SFRH%2FBD%2F151081%2F2021/PT-
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA%2FP%2F0070%2F2020/PT-
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/951723/EU-
dc.relation.ispartofseriesPharmaceutics, vol. 14(12):2745pt_PT
dc.rightsopenAccesspt_PT
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectH. pyloript_PT
dc.subjectNLCpt_PT
dc.subjectAntimicrobialpt_PT
dc.subjectGut microbiotapt_PT
dc.subjectNanoparticlespt_PT
dc.subjectNanostructured lipid carrierspt_PT
dc.subjectProtein coronapt_PT
dc.titleHow Charge, Size and Protein Corona Modulate the Specific Activity of Nanostructured Lipid Carriers (NLC) against Helicobacter pyloript_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Investigação e Inovação em Saúdept_PT
dc.identifier.doi10.3390/pharmaceutics14122745-
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/14/12/2745-
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.3390-pharmaceutics14122745.pdf10.56 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons